Previous 10 | Next 10 |
Daré Bioscience, Inc. (DARE) Q3 2021 Earnings Conference Call November 10, 2021, 04:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Strategy Officer Lisa Walters-Hoffert - CFO Conference Call Participants Zegbeh Jallah - ROTH Capital Partners ...
Significant progress on several key clinical and corporate initiatives with the portfolio during the third quarter, including DARE-BV1 NDA acceptance and Ovaprene NIH CRADA for the pivotal Phase 3 Actively advancing clinical development and strategic partnerships to maximize val...
OTCQX:ACRGF, ADMA, AEVA, DADAAMPE, AMWL, APP, APPH, ASND, ATO, OTCPK:ATUSF, AZUL, BANX, BARK, BIOL, BKEP, BMBL, BOXL, BRFS, BRKS, BROS, BSQR, BW, BYND, BZH, CBAY, CCCS, CCMP, CGRN, CLSD, CLVR, CRCT, CYCC, DARE, DGII, DIS, EDRY, EGLX, ELMS, ENS, EVOK, FICO, FIGS, FOSL, FSM, GAU, GDRX, GEVO, OT...
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conferenc...
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, November 10, 2021, to review its ...
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced its participation in DTC Perspectives’ Xpectives.Health Summit being held in Boston, MA from October 12 – 14, 2021, at The...
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), a division o...
Investigational therapy for women who cannot, or should not, take supplemental estrogen Potential to be the first treatment for vulvar and vaginal atrophy specifically developed for patients with hormone receptor-positive breast cancer, if approved SAN DIEGO, Sept. 23, 2021 (GLOBE...
SAN DIEGO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Virtual Global Healthcare Conference bein...
9 Biotech Penny Stocks For Your October Watchlist Biotech penny stocks have remained some of the hottest small caps to buy over the past year and a half, and there are several good reasons for that. For one, the pandemic has highlighted both the importance of biotech and the potential t...
News, Short Squeeze, Breakout and More Instantly...
2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split...
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies fo...